Cargando…

Diminished Antioxidant Activity of High‐Density Lipoprotein–Associated Proteins in Chronic Kidney Disease

BACKGROUND: Decreased serum arylesterase activity, catalyzed by the high‐density lipoprotein–associated paraoxonase (PON)‐1, is associated with increased oxidant stress and atherosclerosis risk. We sought to determine the prognostic value of serum PON‐1 activity, as monitored by PON or arylesterase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kennedy, David J., Wilson Tang, W. H., Fan, Yiying, Wu, Yuping, Mann, Shirley, Pepoy, Michael, Hazen, Stanley L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647254/ https://www.ncbi.nlm.nih.gov/pubmed/23557751 http://dx.doi.org/10.1161/JAHA.112.000104

Ejemplares similares

Trimethylamine N‐Oxide and Mortality Risk in Patients With Peripheral Artery Disease
por: Senthong, Vichai, et al.
Publicado: (2016)

High-Density Lipoproteins and the Kidney
por: Strazzella, Arianna, et al.
Publicado: (2021)

Intestinal Microbiota‐Generated Metabolite Trimethylamine‐N‐Oxide and 5‐Year Mortality Risk in Stable Coronary Artery Disease: The Contributory Role of Intestinal Microbiota in a COURAGE‐Like Patient Cohort
por: Senthong, Vichai, et al.
Publicado: (2016)

High-Density Lipoproteins in Kidney Disease
por: Kon, Valentina, et al.
Publicado: (2021)

Plasma Nitration of High-Density and Low-Density Lipoproteins in Chronic Kidney Disease Patients Receiving Kidney Transplants
por: Bakillah, Ahmed, et al.
Publicado: (2015)

Chronic kidney disease stage affects small, dense low-density lipoprotein but not glycated low-density lipoprotein in younger chronic kidney disease patients: a cross-sectional study
por: Filler, Guido, et al.
Publicado: (2018)

Prognostic Value of Estimated Functional Capacity Incremental to Cardiac Biomarkers in Stable Cardiac Patients
por: Tang, W. H. Wilson, et al.
Publicado: (2014)

Subfractions of high-density lipoprotein (HDL) and dysfunctional HDL in chronic kidney disease patients
por: Rysz-Górzyńska, Magdalena, et al.
Publicado: (2016)

Association of High-Density Lipoprotein Subclasses with Chronic Kidney Disease Progression, Atherosclerosis, and Klotho
por: Kanda, Eiichiro, et al.
Publicado: (2016)

High-Density Lipoprotein from Chronic Kidney Disease Patients Modulates Polymorphonuclear Leukocytes
por: Raupachova, Jana, et al.
Publicado: (2019)

Indoxyl sulfate and high-density lipoprotein cholesterol in early stages of chronic kidney disease
por: Wang, Li, et al.
Publicado: (2020)

Endothelial lipase increases antioxidative capacity of high-density lipoprotein
por: Schilcher, Irene, et al.
Publicado: (2019)

Subpopulations of High-Density Lipoprotein: Friends or Foes in Cardiovascular Disease Risk in Chronic Kidney Disease?
por: Coimbra, Susana, et al.
Publicado: (2021)

Standardization of a Method to Evaluate the Antioxidant Capacity of High-Density Lipoproteins
por: de Juan-Franco, Elena, et al.
Publicado: (2009)

Low-Density Lipoprotein (LDL)-Antioxidant Biflavonoids from Garcinia madruno
por: Osorio, Edison, et al.
Publicado: (2013)

Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein
Publicado: (1982)

Trajectory of low-density lipoprotein cholesterol in patients with chronic kidney disease and its association with cardiovascular disease
por: Wang, Shih-Wei, et al.
Publicado: (2022)

Effects of serum amyloid A on the structure and antioxidant ability of high-density lipoprotein
por: Sato, Megumi, et al.
Publicado: (2016)

Anti-High-Density Lipoprotein Antibodies and Antioxidant Dysfunction in Immune-Driven Diseases
por: Rodríguez-Carrio, Javier, et al.
Publicado: (2018)

Larrea divaricata: anti-inflammatory and antioxidant effects of on macrophages and low density lipoproteins
por: Peralta, Ignacio, et al.
Publicado: (2022)

The role of lipoprotein (a) in chronic kidney disease
por: Hopewell, Jemma C., et al.
Publicado: (2018)

The role of plasma triglyceride/high-density lipoprotein cholesterol ratio to predict cardiovascular outcomes in chronic kidney disease
por: Sonmez, Alper, et al.
Publicado: (2015)

Small dense low-density lipoprotein cholesterol was associated with future cardiovascular events in chronic kidney disease patients
por: Shen, Hao, et al.
Publicado: (2016)

Non-High-Density Lipoprotein Cholesterol and Progression of Chronic Kidney Disease: Results from the KNOW-CKD Study
por: Suh, Sang Heon, et al.
Publicado: (2022)

Females with angina pectoris have altered lipoprotein metabolism with elevated cholesteryl ester transfer protein activity and impaired high-density lipoproteins-associated antioxidant enzymes
por: PARK, JUNGHO, et al.
Publicado: (2011)

Dysfunctional high-density lipoprotein in chronic inflammatory rheumatic diseases
por: Waldecker-Gall, Sabina, et al.
Publicado: (2023)

Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit
por: Brites, Fernando, et al.
Publicado: (2017)

Correction: Larrea divaricata: anti-inflammatory and antioxidant effects on macrophages and low density lipoproteins
por: Peralta, Ignacio, et al.
Publicado: (2022)

Prognostic value of subclinical myocardial necrosis using high-sensitivity cardiac troponin T in patients with prediabetes
por: Witkowski, Marco, et al.
Publicado: (2021)

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
por: Katsiki, Niki, et al.
Publicado: (2023)

Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
por: Nurmohamed, Nick S, et al.
Publicado: (2021)

Association of Low‐Density Lipoprotein Cholesterol Levels During Statin Treatment With Cardiovascular and Renal Outcomes in Patients With Moderate Chronic Kidney Disease
por: Yen, Chieh‐Li, et al.
Publicado: (2022)

High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes
por: Androulakis, Emmanuel, et al.
Publicado: (2017)

Quantitative glycoproteomics of high-density lipoproteins
por: Tang, Xinyu, et al.
Publicado: (2022)

Non-High-Density Lipoprotein Cholesterol and Cardiovascular Outcomes in Chronic Kidney Disease: Results from KNOW-CKD Study
por: Suh, Sang Heon, et al.
Publicado: (2022)

Lipoprotein Abnormalities in Chronic Kidney Disease and Renal Transplantation
por: Barbagallo, Carlo Maria, et al.
Publicado: (2021)

High Density Lipoproteins and Diabetes
por: Cochran, Blake J., et al.
Publicado: (2021)

Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia
por: McMahon, Kaylin M., et al.
Publicado: (2017)

Increased Antioxidant Quality Versus Lower Quantity of High Density Lipoprotein in Benign Prostatic Hyperplasia
por: Aydin, Ozgur, et al.
Publicado: (2015)

Comparing fluorescence-based cell-free assays for the assessment of antioxidative capacity of high-density lipoproteins
por: Tsunoda, Fumiyoshi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_e4iac8lkl76u0ojtc28qabc8b8